Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke

Background and Purpose— Downstream microvascular thrombosis (DMT) is known to be a contributing factor to incomplete reperfusion in acute ischemic stroke. The aim of this study was to determine the timing of DMT with intravital imaging and to test the hypothesis that intravenous alteplase infusion could reduce DMT in a transient middle cerebral artery occlusion (MCAO) rat stroke model. Methods— Rats were subjected to 60-minute transient MCAO. Alteplase (10 mg/kg) was administered 30 minutes after the beginning of MCAO. Real-time intravital fluorescence microscopy through a dura-sparing craniotomy was used to visualize circulating blood cells and fibrinogen. Cerebral microvessel patency was quantitatively evaluated by fluorescein isothiocyanate-dextran perfusion. Results— Immediately after MCAO, platelet and leukocyte accumulation were observed mostly in the venous compartment. Within 30 minutes after MCAO, microthrombi and parietal fibrin deposits were detected in postcapillary microvessels. Alteplase treatment significantly (P=0.006) reduced infarct volume and increased the percentage of perfused vessels during MCAO (P=0.02) compared with saline. Plasma levels of fibrinogen from alteplase-treated rats showed a rapid and profound hypofibrinogenemia. In vitro platelet aggregation demonstrated that alteplase reduced platelet aggregation (P=0.0001) and facilitated platelet disaggregation (P=0.001). These effects were reversible in the presence of exogenous fibrinogen. Conclusions— Our data demonstrate that DMT is an early phenomenon initiated before recanalization. We further show that alteplase-dependent maintenance of downstream perfusion during MCAO improves acute ischemic stroke outcome through a fibrinogen-dependent platelet aggregation reduction. Our results indicate that early targeting of DMT represents a therapeutic strategy to improve the benefit of large artery recanalization in acute ischemic stroke.

[1]  C. Kahn,et al.  Diabetes primes neutrophils to undergo NETosis, which impairs wound healing , 2015, Nature Medicine.

[2]  H. Diener,et al.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. , 2015, The New England journal of medicine.

[3]  A. Demchuk,et al.  Thrombectomy within 8 hours after symptom onset in ischemic stroke. , 2015, The New England journal of medicine.

[4]  H. Arai,et al.  Endovascular Treatment for Ischemic Stroke , 2015 .

[5]  R. Leker,et al.  Is Bridging Necessary? A Pilot Study of Bridging versus Primary Stentriever-Based Endovascular Reperfusion in Large Anterior Circulation Strokes. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[6]  M. Krause,et al.  Endovascular therapy for ischemic stroke with perfusion-imaging selection. , 2015, The New England journal of medicine.

[7]  Eric E. Smith,et al.  Randomized assessment of rapid endovascular treatment of ischemic stroke. , 2015, The New England journal of medicine.

[8]  Hester F. Lingsma,et al.  A randomized trial of intraarterial treatment for acute ischemic stroke. , 2015, The New England journal of medicine.

[9]  F. Sallustio,et al.  Thrombectomy within 8 hours after symptom onset in ischemic stroke , 2015 .

[10]  Hester F. Lingsma,et al.  MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial , 2014, Trials.

[11]  D. Vivien,et al.  Lack of secondary microthrombosis after thrombin‐induced stroke in mice and non‐human primates , 2014, Journal of thrombosis and haemostasis : JTH.

[12]  M. Hennerici,et al.  Treatment with tPA Predicts Better Outcome Even if MCA Occlusion Persists , 2013, International journal of stroke : official journal of the International Stroke Society.

[13]  P. Gresele,et al.  Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. , 2013, Blood.

[14]  S. Kiechl,et al.  Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis , 2013, Neurology.

[15]  E. Arsava,et al.  Can Restoring Incomplete Microcirculatory Reperfusion Improve Stroke Outcome after Thrombolysis? , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  J. Schmitt,et al.  Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. , 2012, Blood.

[17]  Manabu Inoue,et al.  MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study , 2012, The Lancet Neurology.

[18]  A. Walch,et al.  Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo , 2012, The Journal of experimental medicine.

[19]  J. Serfaty,et al.  Outcomes of Mechanical Endovascular Therapy for Acute Ischemic Stroke: A Clinical Registry Study and Systematic Review , 2011, Stroke.

[20]  J. Michel,et al.  Protective Effect of High-Density Lipoprotein-Based Therapy in a Model of Embolic Stroke , 2010, Stroke.

[21]  Martin Bendszus,et al.  Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI , 2010, NeuroImage.

[22]  M. Wintermark,et al.  Reperfusion Is a More Accurate Predictor of Follow-Up Infarct Volume Than Recanalization: A Proof of Concept Using CT in Acute Ischemic Stroke Patients , 2010, Stroke.

[23]  A. Chauhan,et al.  von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. , 2009, Blood.

[24]  P. Barber,et al.  Assessing Reperfusion and Recanalization as Markers of Clinical Outcomes After Intravenous Thrombolysis in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) , 2009, Stroke.

[25]  Marc Fisher,et al.  Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations , 2009, Stroke.

[26]  A. Demchuk,et al.  Hyperfibrinogenemia and functional outcome from acute ischemic stroke. , 2009, Stroke.

[27]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[28]  Keith Muir,et al.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.

[29]  G. Stoll,et al.  Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding , 2007, Circulation.

[30]  M. Hennerici,et al.  Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial , 2006, The Lancet.

[31]  K. Stokes,et al.  CD40/CD40 Ligand Signaling in Mouse Cerebral Microvasculature After Focal Ischemia/Reperfusion , 2005, Circulation.

[32]  John H. Zhang,et al.  Platelet–Leukocyte–Endothelial Cell Interactions after Middle Cerebral Artery Occlusion and Reperfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  P. Adeleine,et al.  Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases , 2004, Stroke.

[34]  G. D. del Zoppo,et al.  Cerebral Microvessel Responses to Focal Ischemia , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  M. Chopp,et al.  Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic Stroke , 2003, Circulation.

[36]  M. Chopp,et al.  Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion , 2001, Brain Research.

[37]  D. Levy,et al.  Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. , 2000, JAMA.

[38]  J. Orozco,et al.  Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. , 2000, Stroke.

[39]  M. Chopp,et al.  Cerebral Microvascular Obstruction by Fibrin is Associated with Upregulation of PAI-1 Acutely after Onset of Focal Embolic Ischemia in Rats , 1999, The Journal of Neuroscience.

[40]  E. Connolly,et al.  Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. , 1998, The Journal of clinical investigation.

[41]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[42]  J. Koziol,et al.  Fibrin Contributes to Microvascular Obstructions and Parenchymal Changes During Early Focal Cerebral Ischemia and Reperfusion , 1994, Stroke.

[43]  C. Francis,et al.  Fibrinogen‐ and Fibrin‐Degradation Products during Fibrinolytic Therapy a , 1992, Annals of the New York Academy of Sciences.

[44]  G. D. del Zoppo,et al.  Inhibition of Polymorphonuclear Leukocyte Adherence Suppresses No‐Reflow After Focal Cerebral Ischemia in Baboons , 1992, Stroke.

[45]  G. Schmid-Schönbein,et al.  Polymorphonuclear Leukocytes Occlude Capillaries Following Middle Cerebral Artery Occlusion and Reperfusion in Baboons , 1991, Stroke.

[46]  D. Mathey,et al.  Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates. , 1990, Cardiovascular research.

[47]  J. Loscalzo,et al.  Tissue plasminogen activator promotes platelet disaggregation in plasma. , 1987, The Journal of clinical investigation.

[48]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[49]  A. Clauss.  [Rapid physiological coagulation method in determination of fibrinogen]. , 1957, Acta haematologica.